Vicapsys Life Sciences (VICP) 10-K 16 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 15, 2022	Jan. 13, 2022	Jun. 30, 2021
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-56145
Entity Registrant Name	VICAPSYS LIFE SCIENCES, INC.
Entity Central Index Key	0001468639
Entity Tax Identification Number	91-1930691
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	7778 Mcginnis Ferry Rd. #270
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	(972)
Local Phone Number	891-8033
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float				$ 11,646,230
Entity Common Stock, Shares Outstanding		30,814,564
ICFR Auditor Attestation Flag	false
Auditor Name	D. Brooks and Associates CPAs, P.A.
Auditor Location	Palm Beach Gardens, Florida
Auditor Firm ID	4048
Series A Preferred Stock [Member]
Shares issued upon conversion			10,440,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 217,295	$ 1,269
Prepaid Expenses	5,498
Total Current Assets	222,793	1,269
Intangible asset, net of accumulated amortization of $120,994 and $89,665, respectively	371,520	402,849
Total Assets	594,313	404,118
Current Liabilities:
Accounts payable	487,792	501,732
Accounts payable, related parties	112,860	236,180
Accrued salaries, related parties	115,312	115,312
Total Current Liabilities	715,964	853,224
Stockholders’ Deficit:
Common Stock, par value $0.001; 300,000,000 shares authorized; 19,747,283 and 17,483,283 shares issued and outstanding, respectively	19,747	17,483
Common stock to be issued, par value $0.001; 11,067,281 and 651,281 shares outstanding, respectively	11,067	651
Additional paid-in capital	13,977,160	13,418,074
Accumulated deficit	(14,129,625)	(13,892,754)
Total Stockholders’ Deficit	(121,651)	(449,106)
Total Liabilities and Stockholders’ Deficit	594,313	404,118
Series A Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value		3,000
Series B Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock value		$ 4,440

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Intangible asset, net of accumulated amortization	$ 120,994	$ 89,665
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	19,747,283	17,483,283
Common stock, shares outstanding	19,747,283	17,483,283
Common stock to be issued, par value	$ 0.001	$ 0.001
Common stock to be issued, shares outstanding	11,067,281	651,281
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	3,000,000
Preferred stock, shares outstanding	0	3,000,000
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,440,000	4,440,000
Preferred stock, shares issued	0	4,440,000
Preferred stock, shares outstanding	0	4,440,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues
Operating Expenses:
Personnel costs	91,502	286,327
Research and development expenses, related party	17,698	102,180
Professional fees	191,881	330,380
General and administrative expenses	35,790	46,957
Total operating expenses	336,871	765,844
Loss from operations	(336,871)	(765,844)
Other income:
Other income	100,000
Total other income	100,000
Loss before income taxes	(236,871)	(765,844)
Income taxes
Net loss	$ (236,871)	$ (765,844)
Loss per share basic and diluted	$ (0.01)	$ (0.04)
Basic and diluted weighted average common shares outstanding	17,656,762	17,483,283

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3,000	$ 4,440	$ 17,483	$ 651	$ 13,403,293	$ (13,126,910)	$ 301,957
Beginning balance, shares at Dec. 31, 2019	3,000,000	4,440,000	17,483,283	651,281
Stock-based compensation expense					14,781		14,781
Net loss						(765,844)	(765,844)
Ending balance, value at Dec. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,418,074	(13,892,754)	(449,106)
Ending balance, shares at Dec. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Conversion of Series A Preferred Stock to common stock to be issued	$ (3,000)			$ 6,000	(3,000)
Conversion of Series A Preferred Stock to common stock to be issued, shares	(3,000,000)			6,000,000
Conversion of Series B Preferred Stock to common stock		$ (4,440)		$ 4,440
Conversion of Series B Preferred Stock to common stock, shares		(4,440,000)		4,440,000
Common stock issued for common stock to be issued			$ 24	$ (24)
Common stock issued for common stock to be issued, shares			24,000	(24,000)
Sale of common stock for cash			$ 2,240		557,760		560,000
Sale of common stock for cash, shares			2,240,000
Stock-based compensation expense					4,326		4,326
Net loss						(236,871)	(236,871)
Ending balance, value at Dec. 31, 2021			$ 19,747	$ 11,067	$ 13,977,160	$ (14,129,625)	$ (121,651)
Ending balance, shares at Dec. 31, 2021			19,747,283	11,067,281

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss	$ (236,871)	$ (765,844)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	31,329	31,424
Stock-based compensation	4,326	14,781
Gain on sale of equity method investment	(100,000)
Changes in operating assets and liabilities:
Prepaid Expenses	(5,498)
Accounts payable	(13,940)	105,250
Accounts payable, related party	(123,320)	236,180
Accrued salaries, related party		115,312
Net Cash Used in Operating Activities	(443,974)	(262,897)
Cash Flows from Investing Activities:
Proceeds from sale of equity method investment	100,000
Net Cash Used in Investing Activities	100,000
Cash Flows from Financing Activities:
Proceeds from sale of common stock	560,000
Net Cash Provided By Financing Activities	560,000
Net Increase (Decrease) in Cash	216,026	(262,897)
Cash, Beginning of year	1,269	264,166
Cash, End of year	$ 217,295	$ 1,269

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	NOTE 1 - ORGANIZATION Business Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 0.001 20,000,000 0.001 The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S PLANS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND MANAGEMENT’S PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $ 236,871 493,171 14,129,625 In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations. The Company raised $ 560,000 (see Note 10) during the year ended December 31, 2021 and management intends to raise additional funds in 2022 to support current operations and extend research and development of its product line. No assurance can be given that the Company will be successful in this effort. If the Company is unable to raise additional funds in 2022, it will be forced to severely curtail all operations and research and development activities.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Emerging Growth Company The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2021, and 2020, include useful life of property and equipment (prior to disposal, ss Notes 3 and 9) and intangible assets, valuation allowance for deferred tax asset and non-cash equity transactions and stock-based compensation. Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no Intangible Assets Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed. Long-Lived Assets The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2021 and 2020, no such impairments were identified. Equity Method Investment The Company accounts for investments in which the Company owns more than 20 Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $ 100,000 Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments. Revenue Recognition Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2021, and 2020, the Company did not have any revenue. Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation, Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2021, and 2020, the Company recorded $ 17,698 102,180 Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2021, and 2020, the Company’s dilutive securities are convertible into 17,027,281 17,138,006 SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Common stock to be issued 11,067,281 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 1,900,000 Warrants to purchase common stock 4,060,725 4,146,725 17,027,281 17,138,006 Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements for the years ended December 31, 2021, and 2020.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 – INTANGIBLE ASSETS The Company’s intangible assets consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 7). The consideration paid for the rights included in the License Agreement was in the form of common stock shares. The estimated value of the common stock is being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed which was approximately 16 The Company’s intangible assets consisted of the following at December 31, 2021, and 2020: SCHEDULE OF INTANGIBLE ASSETS December 31, 2021 December 31, 2020 Licensed patents $ 492,514 $ 492,514 Accumulated Amortization (120,994 ) (89,665 ) Balance $ 371,520 $ 402,849 The Company recognized $ 31,329 31,424 Future expected amortization of intangible assets is as follows: SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS Fiscal year ending December 31, 2022 $ 31,299 2023 31,299 2024 31,299 2025 31,299 2026 31,299 Thereafter 215,025 Balance $ 371,520

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS Consulting Agreements On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Mark Poznansky, MD (the “Consultant”), a minority stockholder and former Director. The Company engaged the Consultant to render consulting services with respect to informing, guiding and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Consulting Agreement is for one year (the “Initial Term”) and the Company agreed to pay the Consultant $ 3,000 6,000 st 5 0 18,000 9,000 Accounts Payable, related Parties, and Accrued Salaries, related party The Company incurred director fees of $ 90,000 for the years ended December 31, 2021, and 2020, respectively, to Federico Pier, the Company’s Executive Chairman of the Board and Chief Executive Officer, which are included in personnel costs on the consolidated statements of operations. As of December 31, 2021, and 2020, $ 60,000 and $ 75,000 , respectively, of these director fees are included in accounts payable, related parties, on the consolidated balance sheets. The Company incurred consulting fees of $ 60,000 40,000 45,000 In August 2020, Frances Tonneguzzo, the Company’s then-Chief Executive Officer (the “former CEO”), tendered her resignation as CEO. For the years ended December 31, 2021, and 2020, the Company incurred expenses of $- 0 172,354 115,312 Sale of Equity Method Investment In January 2021, the Company sold its equity investment in AEI back to AEI for $ 100,000 MGH License Agreement On May 8, 2013, VI and MGH, a principal stockholder (see Note 6), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”). As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates. Pre-Sales Diligence Requirement: (x) The Company shall provide a detailed business plan and development plan by June 1 st (xi) The Company shall raise $2 million in financing by December 1 st (xii) The Company shall raise an additional $8 million in financing by December 1 st (xiii) The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1 st (xiv) The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1 st (xv) The Company shall initiate research regarding other applications of the CXCL12 platform by June 1 st (xvi) The Company shall initiate a Phase I clinical trial of a Product or Process by March 1 st (xvii) The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date. (xviii) The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date. Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates. Post-Sales Diligence Requirements: (i) The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan. (ii) Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company. In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments: (i) Prior to the First Commercial Sale, the Company shall pay to Hospital a non-refundable annual license fee of ten thousand dollars ($ 10,000 (ii) Following the First Commercial Sale, Company shall pay Hospital a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($ 100,000 The License Agreement also requires VI to pay to MGH a 1 The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement. The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH. VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes. The Company incurred costs to MGH of $ 17,698 102,180 3,860 101,180 During the years ended December 31, 2021, and 2020, there have not been any sales of Product or Process under this License Agreement.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6– COMMITMENTS AND CONTINGENCIES Legal Matters The Company is not aware of any material, existing or pending legal proceedings against our Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest. MGH License Agreement As discussed in Note 5, the Company executed a License Agreement with MGH. The License Agreement also requires VI to pay to MGH a 1 The License Agreement additionally requires VI to pay to MGH a $ 1.0 Consulting Agreement On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with C&H Capital, Inc. (the “Consultant”). The Company engaged the Consultant to render consulting services to facilitate long range strategic investor relations planning and other related services. The initial term of the Consulting Agreement is for one year (the “Initial Term”) and the Company agreed to pay the Consultant $ 3,500 0 21,000 14,000

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock The Company has 20,000,000 0.001 Series A Preferred Stock On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $ 0.001 3,000,000 Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. 1.67 Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into 6,000,000 As of December 31, 2021, and 2020, there were - 0 3,000,000 Series B Preferred Stock On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $ 0.001 4,440,000 Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. 0.83 The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into 4,440,000 As of December 31, 2021, and 2020, there were - 0 4,440,000 Common Stock The Company has 300,000,000 0.001 During the year ended December 31, 2021, the Company sold 2,240,000 0.25 560,000 24,000 19,747,283 17,483,283 Common Stock to be issued On February 12, 2021, the Company recorded 6,000,000 shares of common stock to be issued to the holders of Series A Preferred Stock, pursuant to the automatic conversion feature of the Series A Certificate of Designation, whereby, the Series A shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. On February 12, 2021, the Company recorded 4,440,000 shares of common stock to be issued to the holders of Series B Preferred Stock, pursuant to the automatic conversion feature of the Series B Certificate of Designation, whereby, the Series B shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. As of December 31, 2021, and 2020, there were 11,067,281 651,281 6,000,000 4,440,000 597,281 1.85 30,000 621,281 30,000 Stock Options The following table summarizes activities related to stock options of the Company for the years ended December 31, 2021, and 2020: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Options Weighted- Weighted- Aggregate Intrinsic Outstanding at January 1, 2020 2,450,000 $ 0.57 8.20 $ - Forfeited (550,000 ) $ 0.25 7.94 $ - Outstanding at December 31, 2020 1,900,000 $ 0.66 6.83 $ - Outstanding at December 31, 2021 1,900,000 $ 0.66 5.83 $ - Exercisable at December 31, 2021 1,883,333 $ 0.67 5.82 $ - The Company did no 550,000 options to purchase common stock were forfeited. The Company recorded stock compensation expense of $ 4,326 and $ 14,781 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, 16,667 options to purchase shares of common stock remain unvested and $ 1,163 of stock compensation expense remains unrecognized and is being expensed over a weighted average period of .5 years from the date of the grant. Warrants The following table summarizes activities related to warrants of the Company for the years ended December 31, 2021, and 2020: SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remining Life (Years) Outstanding and exercisable at January 1, 2020 4,146,725 $ 0.53 2.50 Outstanding an exercisable at December 31, 2020 4,146,725 $ 0.53 1.50 Expired (86,725 ) 1.85 Outstanding and exercisable at December 31, 2021 4,060,000 $ 0.53 0.50

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2021, the Company had a net operating loss (“NOL”) carryforward of approximately $ 12,176,000 . NOLs generated prior to 2018, will expire during the years 2033 to 2039 . NOLs generated after 2018 have an indefinite period of use but are subject to annual limitations. Realization of any portion of the NOL at December 31, 2021, is not considered more likely than not by management given the uncertainty in generating taxable income Therefore, a valuation allowance has been established for the full tax amount, which as of December 31, 2021, was $ 2,557,055 . The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2021, and 2020, is as follows: SCHEDULE OF VALUATION ALLOWANCE 2021 2020 Year Ended December 31, 2021 2020 Pre-tax loss $ (26,871 ) $ (765,844 ) U.S. federal corporate income tax rate 21 % 21 % Expected U.S. income tax credit (49,743 ) (160,827 ) Permanent differences 906 3,104 Change in valuation allowance 48,836 157,723 Tax expense $ - $ - The Company had deferred tax assets as follows: SCHEDULE OF DEFERRED TAX ASSETS 2021 2020 Year Ended December 31, 2021 2020 Tax loss carryforward $ 2,557,055 $ 2,508,219 Valuation allowance (2,557,055 ) (2,508,219 ) Net deferred tax assets $ - $ - The Company’s NOL carryforwards may be significantly limited under the Internal Revenue Code (“IRC”). NOL carryforwards are limited under Section 382 when there is a significant ownership change as defined in the IRC. During the year ended December 31, 2017, and previous years, the Company may have experienced such ownership changes, which could pose limitations.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS On January 1, 2022, the Company entered into a consulting agreement (the “Consulting Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Consulting Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant will receive $ 5,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
Emerging Growth Company	Emerging Growth Company The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2021, and 2020, include useful life of property and equipment (prior to disposal, ss Notes 3 and 9) and intangible assets, valuation allowance for deferred tax asset and non-cash equity transactions and stock-based compensation.
Cash	Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no
Intangible Assets	Intangible Assets Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.
Long-Lived Assets	Long-Lived Assets The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2021 and 2020, no such impairments were identified.
Equity Method Investment	Equity Method Investment The Company accounts for investments in which the Company owns more than 20 Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $ 100,000
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2021 and 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.
Revenue Recognition	Revenue Recognition Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2021, and 2020, the Company did not have any revenue.
Stock-based Compensation	Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,
Research and Development	Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2021, and 2020, the Company recorded $ 17,698 102,180
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2021, and 2020, the Company’s dilutive securities are convertible into 17,027,281 17,138,006 SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Common stock to be issued 11,067,281 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 1,900,000 Warrants to purchase common stock 4,060,725 4,146,725 17,027,281 17,138,006
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements for the years ended December 31, 2021, and 2020.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE	SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE December 31, 2021 December 31, 2020 Common stock to be issued 11,067,281 651,281 Convertible preferred stock - 10,440,000 Stock options 1,900,000 1,900,000 Warrants to purchase common stock 4,060,725 4,146,725 17,027,281 17,138,006

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS	The Company’s intangible assets consisted of the following at December 31, 2021, and 2020: SCHEDULE OF INTANGIBLE ASSETS December 31, 2021 December 31, 2020 Licensed patents $ 492,514 $ 492,514 Accumulated Amortization (120,994 ) (89,665 ) Balance $ 371,520 $ 402,849
SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS	Future expected amortization of intangible assets is as follows: SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS Fiscal year ending December 31, 2022 $ 31,299 2023 31,299 2024 31,299 2025 31,299 2026 31,299 Thereafter 215,025 Balance $ 371,520

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	The following table summarizes activities related to stock options of the Company for the years ended December 31, 2021, and 2020: SCHEDULE OF STOCK OPTIONS ACTIVITY Number of Options Weighted- Weighted- Aggregate Intrinsic Outstanding at January 1, 2020 2,450,000 $ 0.57 8.20 $ - Forfeited (550,000 ) $ 0.25 7.94 $ - Outstanding at December 31, 2020 1,900,000 $ 0.66 6.83 $ - Outstanding at December 31, 2021 1,900,000 $ 0.66 5.83 $ - Exercisable at December 31, 2021 1,883,333 $ 0.67 5.82 $ -
SCHEDULE OF WARRANTS ACTIVITY	The following table summarizes activities related to warrants of the Company for the years ended December 31, 2021, and 2020: SCHEDULE OF WARRANTS ACTIVITY Number of Warrants Weighted Average Exercise Price Per Share Weighted Average Remining Life (Years) Outstanding and exercisable at January 1, 2020 4,146,725 $ 0.53 2.50 Outstanding an exercisable at December 31, 2020 4,146,725 $ 0.53 1.50 Expired (86,725 ) 1.85 Outstanding and exercisable at December 31, 2021 4,060,000 $ 0.53 0.50

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF VALUATION ALLOWANCE	A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2021, and 2020, is as follows: SCHEDULE OF VALUATION ALLOWANCE 2021 2020 Year Ended December 31, 2021 2020 Pre-tax loss $ (26,871 ) $ (765,844 ) U.S. federal corporate income tax rate 21 % 21 % Expected U.S. income tax credit (49,743 ) (160,827 ) Permanent differences 906 3,104 Change in valuation allowance 48,836 157,723 Tax expense $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS	The Company had deferred tax assets as follows: SCHEDULE OF DEFERRED TAX ASSETS 2021 2020 Year Ended December 31, 2021 2020 Tax loss carryforward $ 2,557,055 $ 2,508,219 Valuation allowance (2,557,055 ) (2,508,219 ) Net deferred tax assets $ - $ -

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - $ / shares	Sep. 13, 2017	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share.
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001

GOING CONCERN AND MANAGEMENT__2

GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 236,871	$ 765,844
Working capital	493,171
Accumulated deficit	14,129,625	$ 13,892,754
Additional funds raised	$ 560,000

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	17,027,281	17,138,006
Common Stock To Be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	11,067,281	651,281
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		10,440,000
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,900,000	1,900,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,060,725	4,146,725

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
cash equivalents	$ 0	$ 0
Equity method investment, ownership percentage	20.00%
Proceeds from sale of equity method investments	$ 100,000
Research and development expenses	$ 17,698	$ 102,180
Antidilutive securities	17,027,281	17,138,006
Athens Encapsulation Inc [Member]
Proceeds from sale of equity method investments	$ 100,000

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed patents	$ 492,514	$ 492,514
Accumulated Amortization	(120,994)	(89,665)
Balance	$ 371,520	$ 402,849

SCHEDULE OF FUTURE AMORTIZATION

SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 31,299
2023	31,299
2024	31,299
2025	31,299
2026	31,299
Thereafter	215,025
Balance	$ 371,520	$ 402,849

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - License Agreement [Member] - Massachusetts General Hospital [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets remaining amortized period	16 years
Amortization of Intangible Assets	$ 31,329	$ 31,424

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Mar. 14, 2022	Jun. 21, 2019	Dec. 22, 2017	Dec. 31, 2021	Dec. 31, 2020	Jul. 30, 2022
Related Party Transaction [Line Items]
Accounts payable				$ 112,860	$ 236,180
Professional fees				191,881	330,380
Accrued salaries				115,312	115,312
Proceeds from sale of equity method investment				100,000
Research and development expenses				17,698	102,180
Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Accounts payable				3,860	101,180
Research and development expenses				17,698	102,180
Forecast [Member]
Related Party Transaction [Line Items]
Annual license fee						$ 10,000
Royalty expense	$ 100,000
Federico Pier [Member]
Related Party Transaction [Line Items]
Accounts payable				60,000	75,000
Professional fees					90,000
Jeff Wright [Member]
Related Party Transaction [Line Items]
Accounts payable				40,000	45,000
Professional fees				60,000	60,000
Former CEO [Member]
Related Party Transaction [Line Items]
Incurred salaries				0	172,354
CEO [Member]
Related Party Transaction [Line Items]
Accrued salaries				115,312	115,312
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party expenses				0	18,000
Accounts payable				9,000	$ 9,000
License Agreement [Member]
Related Party Transaction [Line Items]
Royalty rate on sales			1.00%
Related parties, description			The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.
License Agreement [Member] | Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Payment to related party				$ 1,000,000
Initial Term [Member] | Consultant [Member] | Consulting Agreement [Member]
Related Party Transaction [Line Items]
Payment to related party		$ 3,000
Fees increasing		6,000
Fundraising amount		$ 5,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jun. 21, 2019	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Professional fees		$ 191,881	$ 330,380
Accounts payable		$ 487,792	501,732
License Agreement [Member] | Massachusetts General Hospital [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage for royalty		1.00%
License agreement, description		The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. No expense reimbursements were paid to MGH during the year ended December 31, 2021 and 2020.
Payment for related party		$ 1,000,000
Consulting Agreement [Member] | C and H Capital, Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for related party	$ 3,500
Professional fees		0	21,000
Accounts payable		$ 14,000	$ 14,000

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options, Outstanding, balance	1,900,000	2,450,000
Weighted-Average Exercise Price per Share, Outstanding, Beginning	$ 0.66	$ 0.57
Weighted-Average Remaining Life (Years), Outstanding, Beginning		8 years 2 months 12 days
Number of Option, Aggregate Intrinsic Value - Beginning
Number of Options, Forfeited		(550,000)
Weighted-Average Exercise Price per Share, Forfeited		$ 0.25
Weighted-Average Remaining Life (Years), Forfeited		7 years 11 months 8 days
Number of Options, Forfeited - Aggregate Intrinsic Value
Weighted-Average Remaining Life (Years), Outstanding, Ending	5 years 9 months 29 days	6 years 9 months 29 days
Number of Options, Outstanding, balance	1,900,000	1,900,000
Weighted-Average Exercise Price per Share, Outstanding, Ending	$ 0.66	$ 0.66
Number of Option, Aggregate Intrinsic Value - Ending
Number of Options, Exercisable	1,883,333
Weighted-Average Exercise Price per Share, Exercisable	$ 0.67
Weighted-Average Remaining Life (Years), Exercisable	5 years 9 months 25 days
Exercisable, Aggregate Intrinsic Value

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options, Outstanding and Execisable, Beginning	4,146,725	4,146,725
Weighted-Average Exercise Price per Share, Outstanding and Exercisable, Beginnig	$ 0.53	$ 0.53
Weighted-Average Remaining Life (Years), Outstanding		2 years 6 months
Weighted-Average Remaining Life (Years), Outstanding		1 year 6 months
Number option, Expired	(86,725)
Weighted Average Exercise Price Per Share, Expired	$ 1.85
Number of Options, Outstanding and Execisable, Ending	4,060,000	4,146,725
Weighted-Average Exercise Price per Share, Outstanding and Exercisable, Ending	$ 0.53	$ 0.53
Weighted-Average Remaining Life (Years), Outstanding	6 months

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)	Feb. 12, 2021	Dec. 19, 2017	Dec. 31, 2021	Dec. 31, 2020	Sep. 13, 2017
Class of Stock [Line Items]
Preferred stock, shares authorized			20,000,000	20,000,000	20,000,000
Preferred stock par value			$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized			300,000,000	300,000,000	300,000,000
Common stock par value			$ 0.001	$ 0.001	$ 0.001
Common stock, shares outstanding			19,747,283	17,483,283
Number of common stock to be issued			11,067,281	651,281
Options to purchase common stock were forfeited				550,000
Equity Option [Member]
Class of Stock [Line Items]
Options to purchase common stock were forfeited			0	550,000
Stock compensation expense			$ 4,326	$ 14,781
Options to purchase shares of common stock remain unvested			16,667
Unrecognized stock compensation expense			$ 1,163
Weighted average period for recognition			6 months
Stock Issuance And Release Agreement [Member]
Class of Stock [Line Items]
Number of common stock to be issued				621,281
Shares issued for conversion			597,281
Shares issued price per share			$ 1.85
Stock Issuance And Release Agreement [Member] | Two Initial Shareholders [Member]
Class of Stock [Line Items]
Number of common stock to be issued			30,000
Stock Issuance And Release Agreement [Member] | Two Shareholders [Member]
Class of Stock [Line Items]
Number of common stock to be issued				30,000
Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for common stock to be issued, shares			24,000
Number of common stock to be issued			2,240,000
Private Placement [Member]
Class of Stock [Line Items]
Numbe of common stock sold			2,240,000
Sale of stock price per share			$ 0.25
Consideration received on sale of stock			$ 560,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		3,000,000	3,000,000	3,000,000
Preferred stock par value		$ 0.001	$ 0.001	$ 0.001
Preferred stock voting rights		Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.
Preferred stock conversion price per share		$ 1.67
Preferred stock conversion, description		Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.
Number of common stock to be issued	6,000,000
Preferred stock, shares issued			0	3,000,000
Preferred stock, shares outstanding			0	3,000,000
Number of common stock to be issued	6,000,000
Shares issued for conversion			6,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		4,440,000	4,440,000	4,440,000
Preferred stock par value		$ 0.001	$ 0.001	$ 0.001
Preferred stock voting rights		Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.
Preferred stock conversion price per share		$ 0.83
Preferred stock conversion, description		The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.
Number of common stock to be issued	4,440,000
Preferred stock, shares issued			0	4,440,000
Preferred stock, shares outstanding			0	4,440,000
Number of common stock to be issued	4,440,000
Shares issued for conversion			4,440,000

SCHEDULE OF VALUATION ALLOWANCE

SCHEDULE OF VALUATION ALLOWANCE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Pre-tax loss	$ (26,871)	$ (765,844)
U.S. federal corporate income tax rate	21.00%	21.00%
Expected U.S. income tax credit	$ (49,743)	$ (160,827)
Permanent differences	906	3,104
Change in valuation allowance	48,836	157,723
Tax expense

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Tax loss carryforward	$ 2,557,055	$ 2,508,219
Valuation allowance	(2,557,055)	(2,508,219)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 12,176,000
Net operating loss carryforward expiration period	2033 to 2039
Valuation allowance	$ 2,557,055

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Jan. 01, 2022USD ($)
Subsequent Event [Member] | Consultant [Member] | Consulting Agreement [Member]
Subsequent Event [Line Items]
Consultancy agreement amount	$ 5,000